Pharmaceutical Innovators at 10th Annual PRO & eCOA Congress Reinforce the Importance of eClinical Technologies for Compliant,

  Pharmaceutical Innovators at 10th Annual PRO & eCOA Congress Reinforce the
  Importance of eClinical Technologies for Compliant, Patient-Centric Research

Comprehensive educational event hosted by PHT Corporation continues to advance
the science and technologies of patient reported outcomes (PROs) and eClinical
systems for clinical research that puts the patient first

PRO & eCOA Congress 2014

Business Wire

BOSTON & GENEVA -- April 10, 2014

Attendees at the 10^th Annual PRO & eCOA Congress in Boston last month
reaffirmed the need to use electronic clinical outcome assessment (COA)
Systems as recommended by the FDA PRO Guidance to improve clinical research
and gain regulatory approvals.

The PRO & eCOA Congress, hosted by PHT Corporation, is the premier PRO and
eClinical outcome assessment meeting. It is attended by pharmaceutical and
biotechnology professionals in clinical operations, outsourcing, data
management, eClinical technologies, regulatory affairs, and health outcomes as
well as PRO and eCOA thought leaders, regulators and sites.

Sheila Rocchio, MBA, PHT Vice President of Marketing and Product Management,
said, “This year’s Congress set a new standard for the depth and level of
knowledge, experience and insights shared by participants. It is absolutely
clear from each presentation, workshop and roundtable discussion that eCOA
technologies are the standard for enabling patient-centric clinical research
that speeds the delivery of new drugs and therapies.”

For the first time in Congress history attendees heard the patient
perspective. Renay Houle, Volunteer/Advocate for the Arthritis Foundation New
England Region, shared her experience as a clinical research participant in a
presentation, “The RA Patient Experience: Trials, Treatment & Life with
Rheumatoid Arthritis.”

Kenneth A. Getz, Director of sponsored research programs at Tufts CSDD and the
Founder of CenterWatch, keynoted the event with a presentation on the changing
R&D paradigm and the critical need to engage patients as partners in pre- and
post-approval studies. Other speakers included representatives from Biogen
Idec, Celgene Corporation, Palatin Technologies, QualityMetric Inc. and PHT.
Event sponsors were CenterWatch, Bluebird Inc., Lionbridge Life Sciences,
Intel and Dell.

Also during the Congress customers learned how the PHT SitePad® System was
used by a customer to achieve primary and secondary endpoints for studies of
its drug which achieved FDA approval.

Next month PHT will launch a Patient-Centric Research Video Series to
highlight Congress presentations, the future of the eCOA industry and the
panel session led by Kenneth Getz with contributions from representatives of
PatientsLikeMe, Biogen Idec, and Eli Lilly and Company, as well as PHT Founder
Dr. Stephen Raymond. See how Congress attendees drove the discussion about
eCOA Systems for improved clinical research, participated in educational
sessions, shared experiences and enjoyed networking with peers:

Registration is open for the PRO & eCOA Congress, Europe, 3-5 June in
Barcelona, Spain. Learn more here: The agenda
combines presentations, case studies, workshops and roundtable discussions
that focus on the latest PRO and eCOA innovations, case studies and best
practices. PHT invites all Congress alumni to join the PRO & eCOA Congress
LinkedIn Community to exchange information, ideas and experiences throughout
the year.

Meet PHT at the Outsourcing in Clinical Trials Europe, 21-22 May to be entered
to win one free PRO & eCOA Congress registration and hotel accommodation in

About PHT Corporation
PHT Corporation is the eClinical innovator leading the adoption of
patient-driven mobile apps for better clinical research. The PHT electronic
clinical outcome assessment (eCOA) system collects and reports secure
real-time patient data from the latest mobile devices. PHT scientific,
regulatory and technological expertise combined with quality outcomes data
enable clients to make research decisions with confidence. Sponsors and CROs
have leveraged the PHT Patient Suite in 650+ trials resulting in 16+
regulatory approvals. Visit for more information on PHT. Follow
PHT on LinkedIn, Twitter, Google+ and YouTube.

Photos/Multimedia Gallery Available:



Media contact:
PHT Corporation
Brenda Nashawaty, 617-688-3253
Press spacebar to pause and continue. Press esc to stop.